Agenus Inc. (AGEN) EPS Estimated At $-0.28

April 21, 2018 - By Migdalia James

Agenus Inc. (NASDAQ:AGEN) LogoInvestors sentiment decreased to 1.26 in Q4 2017. Its down 0.08, from 1.34 in 2017Q3. It is negative, as 12 investors sold Agenus Inc. shares while 27 reduced holdings. 24 funds opened positions while 25 raised stakes. 36.32 million shares or 1.74% less from 36.96 million shares in 2017Q3 were reported.
Gsa Cap Partners Ltd Liability Partnership has 13,300 shares. Assetmark Inc holds 19,360 shares or 0% of its portfolio. Artal Gp invested in 2.50M shares or 0.12% of the stock. Sei Invs holds 0% or 2,666 shares in its portfolio. Susquehanna Llp holds 0% or 27,165 shares in its portfolio. Great West Life Assurance Can holds 8,800 shares or 0% of its portfolio. Raymond James And Associate holds 40,000 shares or 0% of its portfolio. Stratos Wealth Ltd owns 194 shares. 349,625 were accumulated by Chicago Equity Prns Limited Liability Company. Blackrock Inc invested in 0% or 4.88M shares. Credit Suisse Ag accumulated 60,860 shares or 0% of the stock. Goldman Sachs Gru has 0% invested in Agenus Inc. (NASDAQ:AGEN). 929 were accumulated by Royal Comml Bank Of Canada. Jpmorgan Chase And holds 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 16,122 shares. Qvt Financial Ltd Partnership reported 0.55% stake.

Analysts expect Agenus Inc. (NASDAQ:AGEN) to report $-0.28 EPS on May, 3.They anticipate $0.10 EPS change or 55.56 % from last quarter’s $-0.18 EPS. After having $-0.35 EPS previously, Agenus Inc.’s analysts see -20.00 % EPS growth. The stock increased 0.53% or $0.02 during the last trading session, reaching $3.78. About 1.45 million shares traded. Agenus Inc. (NASDAQ:AGEN) has risen 19.90% since April 21, 2017 and is uptrending. It has outperformed by 8.35% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company has market cap of $387.67 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.